Astellas Pharma (STU:YPH) Cyclically Adjusted PS Ratio: (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:YPH Astellas Pharma Inc STU:YPH
84 GF Score
Price €13.30
GF Value €12.50
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Astellas Pharma Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Astellas Pharma  (STU:YPH) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Astellas Pharma Cyclically Adjusted PS Ratio Related Terms


Astellas Pharma Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Astellas Pharma's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Astellas Pharma Cyclically Adjusted PS Ratio Chart

Astellas Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.82 2.43 1.77 1.52 2.27

Astellas Pharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.36 1.50 1.82 2.26 1.87

STU:YPH vs LLY, JNJ, ABBV: Cyclically Adjusted PS Ratio Comparison

For the Drug Manufacturers - General subindustry, Astellas Pharma's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Astellas Pharma Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Astellas Pharma's Cyclically Adjusted PS Ratio falls into.


STU:YPH
84GF Score
Astellas Pharma Inc STU:YPH
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Astellas Pharma Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Astellas Pharma's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Astellas Pharma's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=1.926/113.6000*113.6000
=1.926

Current CPI (Jun. 2026) = 113.6000.

Astellas Pharma Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 1.292 98.000 1.498
201612 1.422 98.400 1.642
201703 1.223 98.100 1.416
201706 1.276 98.500 1.472
201709 1.189 98.800 1.367
201712 1.341 99.400 1.533
201803 1.133 99.200 1.297
201806 1.283 99.200 1.469
201809 1.267 99.900 1.441
201812 1.447 99.700 1.649
201903 1.267 99.700 1.444
201906 1.433 99.800 1.631
201909 1.405 100.100 1.594
201912 1.497 100.500 1.692
202003 1.400 100.300 1.586
202006 1.395 99.900 1.586
202009 1.339 99.900 1.523
202012 1.406 99.300 1.608
202103 1.301 99.900 1.479
202106 1.335 99.500 1.524
202109 1.353 100.100 1.535
202112 1.414 100.100 1.605
202203 1.266 101.100 1.423
202206 1.514 101.800 1.689
202209 1.498 103.100 1.651
202212 1.529 104.100 1.669
202303 1.378 104.400 1.499
202306 1.394 105.200 1.505
202309 1.391 106.200 1.488
202312 1.474 106.800 1.568
202403 1.435 107.200 1.521
202406 1.571 108.200 1.649
202409 1.569 108.900 1.637
202412 1.778 110.700 1.825
202503 1.595 111.100 1.631
202506 1.719 111.700 1.748
202509 1.693 112.000 1.717
202512 1.772 113.000 1.781
202603 1.630 112.700 1.643
202606 1.926 113.600 1.926

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Astellas Pharma (STU:YPH) Overvalued in 2026?

Based on GuruFocus' analysis, Astellas Pharma stock appears to be overvalued. The current stock price of €13.30 is trading 6.4% above its estimated GF Value™ of €12.50. GuruFocus considers Astellas Pharma to be Fairly Valued.

Key valuation signals for STU:YPH:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: €12.50 vs. price of €13.30 (6.4% above fair value)
  • GF Score™: 84/100 with 4 warning signs

No single metric tells the full story. See the STU:YPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Astellas Pharma Business Description

Address 2-5-1 Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411
Astellas Pharma Inc is a specialty international pharmaceutical company. The company focuses on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
84GF Score

Get the complete analysis for STU:YPH

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€13.30
Price
€12.50
GF Value